# Efficacy and Safety of CBP-201 in Patients With Moderate to Severe Persistent Asthma With Type 2 Inflammation

> **NCT04773678** · PHASE2 · COMPLETED · sponsor: **Connect Biopharm LLC** · enrollment: 322 (actual)

## Conditions studied

- Moderate to Severe Persistent Asthma

## Interventions

- **DRUG:** CBP-201
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04773678
- **Lead sponsor:** Connect Biopharm LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-05-11
- **Primary completion:** 2023-08-05
- **Final completion:** 2023-09-28
- **Target enrollment:** 322 (ACTUAL)
- **Last updated:** 2024-03-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04773678

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04773678, "Efficacy and Safety of CBP-201 in Patients With Moderate to Severe Persistent Asthma With Type 2 Inflammation". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04773678. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*